SynthesisCurrent allergy and asthma reports2026
Defining the Role and Clinical Relevance of Periostin in Chronic Rhinosinusitis with or without Nasal Polyps: a Systematic Review and Meta-analysis.
Synthesis in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo determine the clinical relevance of periostin as a biomarker in chronic rhinosinusitis with or without nasal polyps (CRSwNP or CRSsNP), with a focus on its utility in disease classification, evaluating disease burden, and monitoring therapeutic outcomes. RECENT
findingsA meta-analysis of 20 studies involving 2,869 patients demonstrated significantly elevated periostin levels in CRSwNP, particularly in patients with comorbid asthma. Serum periostin measurements were more consistent than tissue-based assays. Elevated periostin correlated with eosinophilic inflammation, higher sinus computed tomography opacity score, and overall disease burden. While it may play a role in assessing the effectiveness of treatment, its significance in biological therapy is not reliably shown. Periostin could serve as a useful addition to eosinophil counts when assessing type 2 inflammation in CRSwNP. It has the potential to aid in identifying patients with a substantial disease burden. However, its role in monitoring treatment response remains uncertain and needs more study. Future investigations should focus on its combined use with other biomarkers, relevance to treatment effectiveness, and establishing clinical cut-off points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.